Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
The compounds have exploded in popularity, but big questions about safety and effectiveness are still unresolved.
Scaling a company across borders is difficult. Scaling one whose “product” is human transformation—delivered live, in real time, through conversation—would seem nearly impossible. Yet Landmark, one of ...
Introduction The management of active patients with symptomatic knee osteoarthritis (KnOA) who are too young for total knee arthroplasty poses a specific challenge to clinicians. Research studies show ...
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical ...
Forbes contributors publish independent expert analyses and insights. Serenity Gibbons is a business consultant who covers entrepreneurs. Across industries, businesses today are more automated and ...
Forbes contributors publish independent expert analyses and insights. David Henkin helps organizations and individuals innovate and grow. It might be tempting to believe that growth is purely a matter ...
Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...
The FDA is removing a long-standing warning from hormone-based drugs used to treat menopause symptoms in women. FDA and HHS officials said the labels stemmed from a study published more than 20 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results